Henry Schein, Inc. (NASDAQ:HSIC) SVP Michael S. Ettinger sold 3,671 shares of the firm’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $66.96, for a total transaction of $245,810.16. Following the completion of the sale, the senior vice president now owns 87,972 shares of the company’s stock, valued at $5,890,605.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Shares of NASDAQ HSIC opened at $68.91 on Friday. The stock has a market capitalization of $10.04 billion, a P/E ratio of 16.69, a P/E/G ratio of 2.62 and a beta of 0.85. The company has a 50-day moving average price of $63.16 and a 200-day moving average price of $65.35. Henry Schein, Inc. has a 1 year low of $56.58 and a 1 year high of $72.81. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.63 and a quick ratio of 0.95.
Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, November 5th. The company reported $0.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.86 by $0.04. The firm had revenue of $2.51 billion during the quarter, compared to analysts’ expectations of $2.52 billion. Henry Schein had a net margin of 4.66% and a return on equity of 15.93%. The business’s revenue was up 6.5% on a year-over-year basis. During the same period last year, the company earned $1.03 earnings per share. As a group, equities research analysts anticipate that Henry Schein, Inc. will post 3.45 earnings per share for the current fiscal year.
A number of equities research analysts have commented on the stock. Cleveland Research restated a “hold” rating on shares of Henry Schein in a report on Friday, November 1st. TheStreet upgraded shares of Henry Schein from a “c+” rating to a “b” rating in a report on Monday, October 14th. Zacks Investment Research cut shares of Henry Schein from a “hold” rating to a “sell” rating and set a $71.00 price target for the company. in a report on Wednesday. Barrington Research restated a “buy” rating and issued a $75.00 price target on shares of Henry Schein in a report on Wednesday. Finally, William Blair cut shares of Henry Schein from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 7th. Six research analysts have rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the stock. Henry Schein has an average rating of “Hold” and an average price target of $73.50.
Several hedge funds and other institutional investors have recently modified their holdings of HSIC. Enterprise Financial Services Corp grew its holdings in shares of Henry Schein by 101.3% during the third quarter. Enterprise Financial Services Corp now owns 483 shares of the company’s stock valued at $31,000 after buying an additional 243 shares during the last quarter. Cullen Frost Bankers Inc. acquired a new position in shares of Henry Schein during the second quarter valued at about $36,000. Ibex Wealth Advisors acquired a new position in shares of Henry Schein during the second quarter valued at about $40,000. Meeder Asset Management Inc. acquired a new position in shares of Henry Schein during the second quarter valued at about $59,000. Finally, Rational Advisors LLC grew its holdings in shares of Henry Schein by 24.9% during the second quarter. Rational Advisors LLC now owns 903 shares of the company’s stock valued at $63,000 after buying an additional 180 shares during the last quarter.
Henry Schein Company Profile
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Further Reading: Does a trade war provide a risk to the global economy?
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.